direct oral anticoagulants - search results
If you're not happy with the results, please do another search
Alternative timing method for direct oral anticoagulants following ischaemic stroke with atrial fibrillation deemed...
A new timely practice—known as the “1-2-3-4-day” rule—for the administration of direct oral anticoagulants (DOACs) in patients after acute ischaemic stroke or transient ischaemic...
Boston Scientific initiates trial comparing left atrial appendage closure to direct oral anticoagulants for...
According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...
Apixaban associated with lower risk of gastrointestinal bleeding in AF patients compared to other...
Use of apixaban was associated with a lower risk of gastrointestinal bleed and similar rates of ischaemic stroke or systemic embolism, intracranial haemorrhage and...
Anticoagulants fail to improve survival from COVID-19, Swedish study finds
The use of direct oral anticoagulants (DOACs) did not reduce the rate of hospitalisation, intensive care admission or fatality due to COVID-19, according to...
ACC publishes pathway on the management of bleeding in patients on oral anticoagulants
The American College of Cardiology has published an expert consensus decision pathway (ECDP) on the management of bleeding in patients being treated with direct...
Risk of dementia higher without oral anticoagulants for AF
A retrospective national Swedish registry study by Leif Friberg and Mårten Rosenqvist (Karolinska Institutet, Stockholm, Sweden) has found that the risk of dementia is...
AF patients with intermediate-to-high-risk of stroke often prescribed aspirin instead of anticoagulants
More than one-in-three patients with atrial fibrillation with an intermediate-to-high-risk of stroke are prescribed aspirin instead of oral anticoagulants, despite guidelines recommending the use...
Verseon presents data on new class of anticoagulants at the 8th Biotech Showcase conference
The recently-obtained data demonstrates continuing and steady progress for the drug candidates in Verseon's anticoagulation program, according to a press release.
Insertable cardiac monitors may help decide safe discontinuation of oral anticoagulation in AF patients...
A strategy including insertable cardiac monitors (ICM) to guide rhythm control with antiarrhythmic drugs and assessment of AF burden may allow safe discontinuation of oral anticoagulation in AF patients at high risk of bleeding.
ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion
Results of the X-VERT trial, presented at the European Society of Cardiology meeting (ESC; 30 August–3 September, Barcelona, Spain), showed that rivaroxaban (Bayer/Janssen Pharmaceuticals)...
Novel oral anticoagulants an option for patients with atrial fibrillation
Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.
Clinical strategies for selecting oral anticoagulants in atrial fibrillation patients
With the advent of new oral anticoagulants, there are many questions towards selection of the most appropriate treatment for patients with atrial fibrillation. Sean D Pokorney (Durham, USA) writes for Cardiac Rhythm News about the different clinical strategies to take into consideration based on the results of landmark clinical trials of novel oral anticoagulants.
Indirect comparison of new anticoagulants provides insight into how the drugs compare
Gregory Lip and colleagues have made an indirect comparison of the new anticoagulants. They have found "no profound significant differences" in efficacy between apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) and both does of dabigatran (Pradaxa, Boehringer Ingelheim) and Rivaroxaban (Xarelto, Bayer).
Watchman device shows 75% reduction in stroke risk in patients with atrial fibrillation not...
Vivek Reddy, New York, USA, presented results from the ASA Plavix (ASAP) study of the Watchman Left Atrial Appendage Closure (LAAC) device (Boston Scientific) during a late-breaking session at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston, USA.
Edoxaban: Next generation oral anticoagulant under investigation
New treatment could offer further option in addition to current standard of care in thromboembolic disease in atrial fibrillation patients.
HRS 2021: DOACs reduce risk of stroke in patients undergoing left ventricular RFA
Use of direct oral anticoagulants (DOACs) in patients undergoing ventricular tachycardia radio frequency ablation (RFA) is associated with a reduced risk of transient ischaemic...
DOACs show better safety and effectiveness versus warfarin in patients with valvular AF
Patients with valvular atrial fibrillation (AF) who were new users of direct oral anticoagulants (DOACs) were at lower risk for ischaemic stroke or systemic...
AHA 2020: Rivaroxaban may be comparable to warfarin for bioprosthetic mitral valves, AF
The primary results from the RIVER Trial—Rivaroxaban for Valvular Heart disease and Atrial Fibrillation—show that rivaroxaban is comparable to warfarin for patients with bioprosthetic...
President of Venice Arrhythmias discusses current challenges in atrial fibrillation management
Antonio Raviele (Venice, Italy), the president of Venice Arrhythmias 2019 (3–5 October; Venice, Italy), talks to BLearning Cardio about some of the current challenges in atrial fibrillation (AF)...
Analysis of the BRUISE CONTROL 1 and 2 trials shows no difference in clinically...
By Hannah Woolley
In a multivariate analysis including both BRUISE CONTROL 1 and BRUISE CONTROL 2 patients and adjusted for antiplatelet use, there was no...
New guidelines promote safety for patients on antithrombotic drugs undergoing anaesthesia or pain intervention
Patient safety is the focus of newly published updates to consensus statements that address the use of antithrombotic drugs by individuals who may require...
Less bleeding in ablation with interrupted dabigatran compared to uninterrupted warfarin
The results of ABRIDGE-J, a Japanese multicentre randomised study on minimally interrupted dabigatran vs. uninterrupted warfarin for catheter ablation, were presented during a late-breaking...
Antithrombotic therapy after left atrial appendage closure
Uncertainty exists about the optimal post-interventional antithrombotic drug regimen as well as treatment duration after left atrial appendage closure; Boris Schmidt and KR Julian...
ESC 2021: Edoxaban shown to be noninferior to warfarin for adverse events after TAVI
Edoxaban is noninferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation (TAVI), new...
ACC.21: Registry data show low rate of stroke at one year following LAAO with...
Transcatheter left atrial appendage occlusion (LAAO) with a Watchman (Boston Scientific) device was associated with a low rate of stroke at one year, even...
Boston Scientific initiates CHAMPION-AF trial of Watchman FLX
Boston Scientific has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the Watchman FLX left atrial appendage closure (LAAC) device...
ESC Congress 2020: Guidelines push individualised approach to AF
Patients with arrhythmia should choose the treatment plan with their health professionals, according to European Society of Cardiology (ESC) guidelines published online today in...
First procedures performed in the USA using Watchman FLX LAAC device
Physicians at the Texas Cardiac Arrhythmia Institute (TCAI) at St David's Medical Center in Austin and Los Robles Health System in Thousand Oaks, became...
Prompt diagnosis “vital” in effective AF management
Dhiraj Gupta, consultant cardiologist and electrophysiologist at Liverpool Heart and Chest Hospital, (Liverpool, UK) discusses the current burden of atrial fibrillation (AF) on healthcare...
AF Symposium 2020: Use-as-needed NOAC strategy is safe and effective for selected AF patients
Speaking today at the AF Symposium (23–25 January, Washington, DC, USA), Francis Marchlinski (Hospital of the University of Pennsylvania, Philadelphia, USA) reported that selected...
Pooled analysis shows LAAC is cheaper than drug therapy for AF
A pooled analysis of five-year data from the PROTECT AF and PREVAIL trials has shown left atrial appendage closure (LAAC) to be cost‐effective, and...
White paper from Heart Rhythm Society suggests Afib treatment has reached a “turning point”
The Heart Rhythm Society has published a white paper looking at the consequences of oral anticoagulants for managing stroke risk in atrial fibrillation which...
CE mark for Watchman FLX left atrial appendage closure device
Boston Scientific announced it has received CE mark and initiated a limited market release of the next generation Watchman FLX left atrial appendage closure...
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and...
Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 (Anticoagulation using the direct factor...
Point-of-care testing of coagulation in patients treated with edoxaban
The first systematic evaluation of coagulation point-of-care testing in edoxaban treated patients has been carried out. The results were presented by Florian Härtig, University...
Octreotide enables left atrial appendage closure in AF patients with GI bleeding
Octreotide therapy has the potential to offer atrial fibrillation (AF) patients with arteriovenous malformations (AVM) related gastrointestinal (GI) bleeding another treatment option. It is...
Nassir Marrouche
Nassir Marrouche is a prominent electrophysiologist, executive director of the Comprehensive Arrhythmia Research and Management (CARMA) Centre at the University of Utah in Salt...
Dabigatran consistently shown to decrease risk of brain bleeds compared to warfarin
A new comparative study between dabigatran and warfarin finds similar ischemic stroke risks, but fewer brain bleeds for dabigatron compared with warfarin in US-based...
Vivek Reddy on the final outcomes of PREVAIL and PROTECT-AF
Boston Scientific has announced the final five-year outcomes data from the PREVAIL study during a late-breaking clinical trial session at this year’s Transcatheter Cardiovascular...
Significant differences among atrial fibrillation patients across Asia
The latest results from one of the largest, ongoing global disease registries in atrial fibrillation (AF)— GARFIELD-AF (global anticoagulant registry in the field-atrial fibrillation)...
Carlos Morillo
Carlos Morillo (Calgary, Canada) was one of the first physicians to document the potential of ablation of the pulmonary vein region as a strategy...
Four out of 10 AF patients may not receive necessary stroke-prevention medication
Many patients with an irregular heartbeat, known as atrial fibrillation, are not receiving recommended blood thinning medication they need to prevent strokes, according to...
Surgical left atrial appendage occlusion reduces thromboembolic stroke and mortality in older AF patients
Surgical left atrial appendage occlusion (LAAO) is associated with a reduction of thromboembolism and all-cause mortality among older atrial fibrillation (AF) patients undergoing cardiac...
ACC 2017: Uninterrupted dabigatran performs better than warfarin in atrial fibrillation ablation
Results from the RE-CIRCUIT study have shown that uninterrupted dabigatran (Pradaxa, Boehringer Ingelheim), was associated with fewer bleeding complications than uninterrupted warfarin before, during...
Case strengthens for opportunistic atrial fibrillation screening
By Angela Gonzalez
In the quest to reduce the number of atrial fibrillation (AF) related strokes, which account for a third of all ischaemic strokes,...
Health Canada approves edoxaban for two indications
Health Canada has approved edoxaban (Lixiana, Servier Canada) for the prevention of stroke and for systemic embolic events in patients with non-valvular atrial fibrillation,...
Portola license Japanese commercial rights for andexanet alfa to Bristol-Myers Squibb and Pfizer
Portola has also entered into a clinical collaboration agreement with Bayer HealthCare to include its Factor Xa inhibitor rivaroxaban in this clinical development programme in Japan.
NICE recommends once-daily Lixiana (edoxaban) for preventing stroke and systemic embolism in non-valvular atrial...
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism in patients suffering from atrial fibrillation.
First patient enrolled in study of Eliquis (apixaban) in NVAF patients with recent acute...
This two-by-two factorial, randomised controlled trial will evaluate the safety of Eliquis versus warfarin or other vitamin K antagonists (VKA) in patients with NVAF and a recent acute coronary syndrome or undergoing PCI.
Global registry presents two-year outcomes data in more than 17,000 newly-diagnosed AF patients
These two-year prospective outcomes from cohorts 1 and 2 show a mortality rate of 3.83% per person year compared to stroke rates of 1.25% per person year and major bleeding rates of 0.7% per person year.
Highlights EHRA EUROPACE-CARDIOSTIM 2015: Interview with Michael Glikson
Michael Glikson (director of Davidai Arrhythmia Center, Heart Center, Sheba Medical Center, Tel Hashomer, Israel), vice-chairperson scientific programme for EHRA EUROPACE-CARDIOSTIM 2015, talks to Cardiac Rhythm News about the highlights of this years' congress.
Benefit of anticoagulation in AF patients with a low risk of stroke questioned
The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low risk of stroke.
First patient enrolled in dabigatran study comparing anticoagulation strategies during atrial fibrillation ablation
The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa) during ablation procedures compared to warfarin. Results from the study are expected during 2016.
Phase 3 ANNEXA-R study of andexanet alfa and factor Xa inhibitor Xarelto meets primary...
Andexanet alfa is the only universal factor Xa inhibitor antidote shown to directly reverse the anticoagulant activity of these agents in clinical studies.
Get With The Guidelines-AFIB: A US quality improvement programme for atrial fibrillation patients
Guideline adherence to anticoagulation in atrial fibrillation seems to be more difficult compared to other quality measures in cardiology practice. William Lewis (chair of...
Massimo Santini
Massimo Santini performed the first fulguration of the atrioventricular node of resistant supraventricular tachycardia in Italy; he also implanted a pacemaker in the Italian president Carlo Azeglio Ciampi, 10 years ago. Santini speaks to Cardiac Rhythm News about his views on advances in antiarrhythmic drugs, genetics and cardiac arrhythmias, and ECG screening.
Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary intervention has been published in the European Heart Journal.
Bristol-Myers Squibb and Pfizer to present new Eliquis (apixaban) data at ESC
Bristol-Myers Squibb Company and Pfizer have announced that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, 30 August to 4 September in Barcelona, Spain.
New study of Pradaxa to explore anticoagulation in ablation of AF patients
The RE-CIRCUIT study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa in patients with atrial fibrillation who undergo ablation. Results of the study are expected in 2016.
Daiichi Sankyo initiates phase 3 ENSURE-AF study
The first patient has been enrolled in the largest planned phase 3 study evaluating novel oral anticoagulant edoxaban in non-valvular atrial fibrillation patients undergoing electrical cardioversion.
Detection of atrial fibrillation with insertable cardiac monitors is superior to standard monitoring in...
Results from the CRYSTAL AF trial have shown that atrial fibrillation in patients with cryptogenic stroke is better detected with insertable cardiac monitors than standard monitoring at six, 12 and 36 months.
Rivaroxaban prevents prothrombogenic remodelling of human atrial myocardium
Andreas Goette (Paderborn, Germany) explains the results of a study which found how rivaroxaban (Xarelto, Bayer Healthcare) helps to prevent prothrombogenic remodelling of human atrial myocardium.
UK’s NICE supports improved commissioning for anticoagulation therapy for adults
On 14 May, UK's National Institute for Health and Care Excellence (NICE) issued updated support for commissioners to help them work with clinicians and managers to commission high-quality, evidence-based anticoagulation therapy for adults across England.
Rivaroxaban to be studied with Factor Xa inhibitor antidote
Janssen Pharmaceuticals in conjunction with Portola Pharmaceuticals and Bayer HealthCare will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant activity of rivaroxaban in emergency situations.
The use of dabigatran in clinical practice
Dabigatran (Pradaxa, Boehringer Ingelheim) was the first of three novel anticoagulants, the others being rivaroxaban (Xarelto, Bayer) and apixaban (Eliquis, Bristol Myers Squibb, Pfizer), to be approved for stroke prevention in patients with non-valvular atrial fibrillation. Giuseppe Di Pasquale reviews the use of the drug in clinical practice.
Gregory YH Lip
Gregory YH Lip, Birmingham, UK, talked to Cardiac Rhythm News about the highlights of his career, including his mother as his biggest influence, and the recent update to the European Society of Cardiology (ESC) guidelines for the management of atrial fibrillation.
European Commission approves apixaban for prevention of stroke and systemic embolism in non-valvular atrial...
The European approval for apixaban is supported by the pivotal phase 3 trials ARISTOTLE and AVERROES, which evaluated approximately 24,000 patients with non-valvular atrial fibrillation.
Dabigatran etexilate recommended for approval for stroke prevention in AF patients in Europe
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dabigatran etexilate (Boehringer Ingelheim's Pradaxa) in the member states of the European Union for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk factors.
Worldwide survey shows ablation works without drugs in most cases
Riccardo Cappato, Centre of Clinical Arrhythmia and Electrophysiology, Policlinico San Donato, Milan, makes his case following the second global survey on catheter ablation.
Riccardo Cappato
Riccardo Cappato, from Milan, Italy, spoke to Cardiac Rhythm News about his career, advances in cardiac rhythm management, and his passion for crime fiction.
Voice response system useful for monitoring anticoagulant patients
Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff.
Final patient completes treatment in the RE-LY study
Trial compares dabigatran etexilate with warfarin for the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
